This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Skin Infection
and you are
over 18
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

Primary Objective: To make a preliminary assessment of the efficacy of CG400549 (960 mg daily) in subjects with cABSSSI (major cutaneous abscesses) due to MRSA. Secondary Objective(s): - To assess the pharmacokinetics of CG400549 (960 mg daily) in subjects with cABSSSI due to MRSA - To explore the in vitro susceptibility of cABSSSI-related bacteria to CG400549. - To assess the safety of multiple doses of CG400459

Provided treatments

  • Drug: CG400549

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01593761. The sponsor of the trial is CrystalGenomics, Inc. and it is looking for 20 volunteers for the current phase.
Official trial title:
Phase 2a, Repeated-dose, Open-label, Single-arm Study of CG400549 for the Treatment of Complicated Acute Bacterial Skin and Skin Structure Infection (cABSSSI) Caused by Methicillin-resistant Staphylococcus Aureus (MRSA)